Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€17.34
Change (%) Stock is Down 0.15 (0.86%)
Volume13,083
Data as of 04/25/18 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
24-Apr-2018ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
LYON, France--(BUSINESS WIRE)--Apr. 24, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended Decemb... 
 Printer Friendly Version
16-Apr-2018Erytech: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – March 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Apr. 16, 2018-- Regulatory News: Erytech (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Dat... 
 Printer Friendly Version
12-Apr-2018ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018
LYON, France--(BUSINESS WIRE)--Apr. 12, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA®) in combination with chemotherapy for the treatment of acute lymphoblas... 
 Printer Friendly Version
13-Mar-2018ERYTECH to Webcast Presentation at the Cowen and Company 38th Annual Healthcare Conference
LYON, France--(BUSINESS WIRE)--Mar. 13, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at The Marriott Copley... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top